These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 9367660)

  • 1. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides: a new therapeutic approach.
    Temsamani J; Guinot P
    Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides in cutaneous therapy.
    Wraight CJ; White PJ
    Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antisense nucleotides for therapy].
    Wang J; Wang L; Wang Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Feb; 23(1):230-4. PubMed ID: 16532848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides for therapeutic intervention.
    Eck SL; Nabel GJ
    Curr Opin Biotechnol; 1991 Dec; 2(6):897-904. PubMed ID: 1367966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The application of antisense technology in ophthalmology].
    Guo Y; Ge J
    Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotides for central nervous system tumors.
    Hall WA; Flores EP; Low WC
    Neurosurgery; 1996 Feb; 38(2):376-83. PubMed ID: 8869067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The significance of specific oligonucleotides in clinical medicine and their use in the treatment of patients with infective diseases].
    Bojić I
    Vojnosanit Pregl; 1996; 53(5):399-408. PubMed ID: 9229959
    [No Abstract]   [Full Text] [Related]  

  • 15. Antisense oligonucleotides in cancer.
    Castanotto D; Stein CA
    Curr Opin Oncol; 2014 Nov; 26(6):584-9. PubMed ID: 25188471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense strategies and therapeutic applications.
    Putnam DA
    Am J Health Syst Pharm; 1996 Jan; 53(2):151-60; quiz 182-3. PubMed ID: 8653480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T
    Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.
    Arora V; Devi GR; Iversen PL
    Curr Pharm Biotechnol; 2004 Oct; 5(5):431-9. PubMed ID: 15544491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.